SACRAMENTO, CA –Nov. 17, 2026 – Today, Blood Cancer United applauds California voters for approving Proposition 38, a statewide ballot measure that will fund breakthrough immunology research aimed at advancing treatments for blood cancers and other serious illnesses, including Alzheimer's, Parkinson’s, and heart disease.
Proposition 38 will fund immunology research at eligible California nonprofit universities and research institutions, supporting scientific discoveries that could lead to new treatment options for patients facing blood cancer. Blood Cancer United joined a broad coalition of physicians, nurses, researchers, community organizations, and others in support of the measure. The $8.4 billion from Proposition 38, and the $7.5 billion from the California Science and Health Research Bond Act, mean huge new potential investments in science and research in California.
“The passage of Proposition 38 represents a commitment to scientific innovation and will help support the research needed to develop the next generation of treatments,” said Gwen Nichols, M.D., chief medical officer of Blood Cancer United. “Immunotherapies are already extending and saving lives, and this monumental win will help researchers continue building on that progress.”
Several volunteer advocates helped make this progress possible, including California residents Andrew Dale, Laurie Adami, and Bhavika Taunk.
“Immunotherapies gave me the greatest gift of all: more time,” said Dale. “They allowed me to watch both of my kids graduate. I’m relieved that now more families will have that same opportunity to celebrate more birthdays, anniversaries, and graduations.”
“An immunotherapy clinical trial saved my life—and I’m thrilled that now this same type of innovative treatment will go on to save the lives of countless others,” said Adami.
“Prop 38 passing means that more families will have more time with their loved ones who are fighting cancer. For my family, it means that innovative treatments will continue to get funded so that my son can have more time,” said Taunk.
Blood Cancer United will continue to work with patients, volunteers, partners, and state officials to ensure that these new research dollars are invested transparently and responsibly, with a focus on delivering the best outcomes for patients.
###
About Blood Cancer United®
Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization has consistently evolved to better serve people affected by all 100-plus types of blood cancer. Blood Cancer United funds innovative research, offers free resources and personalized support, and advocates at state and national levels for more accessible and affordable healthcare for all patients. To learn more, visit www.BloodCancerUnited.org.
Media contact:
Kathy Melley, Blood Cancer United